Furthermore, decreased proliferation inhibition was observed after FLT1 knockdown in an RCC lacking methylation of both FLT1 and KDR. These data indicated that the various anti-VEGF/VEGFR drugs tested inhibit cell proliferation through different targets within the VEGF-VEGFR signaling pathway in cancer cells. This evidence concerns the gene VEGFA and cancer.